907. Outcomes Research: Plasma Cell Disorders: Poster III

Real world response and toxicity profiles of sequential bispecific antibody therapies in Relapsed Refractory multiple myeloma

Recruitment strategies and enrollment for an ongoing virtually supervised prehabilitation exercise intervention in patients diagnosed with multiple myeloma scheduled to receive autologous stem cell transplant Preliminary findings

Outcomes for low income patients with multiple myeloma A national retrospective trend analysis from 2015 to 2022

Real world outcomes with teclistamab in relapsed refractory multiple myeloma and severe renal failure A propensity matched multi center retrospective study using trinetx database

Impact of pre existing psychiatric conditions on toxicity and outcomes of patients after BCMA directed CAR T cell therapy

Impact of pre existing central nervous system conditions and cognitive impairments on toxicity and outcomes after BCMA directed CAR T cell therapy

One year outcomes of daratumumab based vs non daratumumab regimens in AL amyloidosis A propensity matched real world study

Real world outcomes in older adults with triple class exposed multiple myeloma

Immune effector cell associated enterocolitis IEC EC across CAR T products in myeloma and lymphoma A real world pharmacovigilance analysis

The importance of autologous stem cell transplant ASCT in multiple myeloma treatment in the lack of novel therapies

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma A prospective mixed methods study

The treatment of patients primary refractory or with sub optimal response to d VTD induction An italian real life Study

Impact of autoimmune disease on outcomes after BCMA directed CAR T cell therapy for patients with multiple myeloma

Myeloma mortality trends in the United States Excluding Puerto Rico 1999–2021 and future projections using ARIMA modeling and machine learning

Characteristics and treatment patterns of nontransplanted patients with newly diagnosed multiple myeloma treated with daratumumab bortezomib lenalidomide and dexamethasone DVRd or daratumumab lenalidomide and dexamethasone DRd in the frontline setting

Real world characteristics and outcomes of newly diagnosed multiple myeloma patients receiving autologous stem cell transplantation 2018–2024 from the honeur network

Bortezomib melphalan prednisone VMP daratumumab DVMP vs lenalidomide dexamethasone Rd daratumumab DRd in transplant ineligible real life multiple myeloma patients Results from the randomized phase IV real MM trial

Pre treatment vaccine seroprotection is markedly lower in BCMA CAR vs CD19 CAR recipients with limited post therapy modulation

Patient perspectives and preferences for step up dosing and treatment with teclistamab and talquetamab Insights from a patient survey

Incidence of cytokine release syndrome CRS immune effector cell associated neurotoxicity syndrome ICANS infections and cardiovascular events between chimeric antigen receptor CAR T cell therapy products in multiple myeloma MM A nationwide analysis

Severe neutropenia after treatment with T cell engaging bispecific antibodies is associated with higher rates of CRS and disease response

Risk stratification based on machine learning for severe cytokine release syndrome in RRMM patients treated with bispecific antibodies

Healthcare Providers knowledge and attitudes toward venous thromboembolism prophylaxis in multiple myeloma A cross sectional survey

T cell redirecting therapies in multiple myeloma Barriers and knowledge gap among patients community physicians and caregivers

Outcomes of elderly patients with newly diagnosed multiple myeloma NDMM A retrospective comparison of daratumumab based induction versus autologous stem cell transplant autoSCT

Reasons for treatment discontinuation in multiple myeloma Insights from the PREAMBLE registry

Visualizing geographic variation and systemic inequities of disease burden and CAR T cell therapy access in multiple myeloma in the US

Determinants of survival in primary plasma cell leukemia PPCL Analysis of a real world pooled database

The burden of myeloma treatment routes and locations on patients and families Insights from a Pan European survey

Real world outcomes of transplant ineligible newly diagnosed multiple myeloma patients treated in the United States with contemporary regimens

Survival trends in systemic amyloidosis over two decades A real world cohort analysis

Bridging Therapy s effects on clinical outcomes after commercial BCMA CAR T cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma

Impact of slim CRAB criteria on treatment initiation in newly diagnosed multiple myeloma in the veteran health administration

Evolution of care and outcomes of kidney transplantation in plasma cell dyscrasias A single center experience